Rani Therapeutics Holdings, Inc. (RANI)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 7.46 |
| Open | 7.50 |
| Bid | 7.04 x 400 |
| Ask | 7.21 x 200 |
| Day's range | 6.99 - 7.68 |
| 52-week range | 1.82 - 8.75 |
| Volume | |
| Avg. volume | 145,147 |
| Market cap | 370.123M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.33 |
| Earnings date | 20 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.00 |
GuruFocus.comRani Therapeutics Q1 2024 Earnings: Financial Performance and Strategic Updates
Insights into Rani Therapeutics' First Quarter Results and Future Clinical Endeavors
GlobeNewswireRani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 - - RaniPill HC to be ready for potential Phase 1 clinical trials in the second half of 2024 - SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral d
Simply Wall St.Favourable Signals For Rani Therapeutics Holdings: Numerous Insiders Acquired Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
© 2024 Yahoo. All rights reserved.